Current status of diagnosis and treatment and progress in drug research and development for hepatitis D
10.3760/cma.j.cn501113-20240612-00292
- VernacularTitle:丁型肝炎诊疗现状及药物研发进展
- Author:
Huiying RAO
1
;
Lai WEI
Author Information
1. 北京大学人民医院 北京大学肝病研究所 北京大学人民医院感染与肝病中心，北京 100044
- Keywords:
Hepatitis D;
Hepatitis D virus;
Drug development;
Diagnosis;
Treatment;
Screening
- From:
Chinese Journal of Hepatology
2024;32(10):948-954
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis D is a kind of severe viral hepatitis caused by co-infection with hepatitis D virus (HDV) and hepatitis B virus (HBV) or infection with HDV on the ground of HBV infection. Patients with hepatitis D who are infected with HBV often have faster disease progression and a worse prognosis. However, the public and clinicians have always paid little attention to chronic hepatitis D. Coupled with the limitations of detection methods and the absence of a screening system, the HDV screening rate in various regions of the world is at a low level. Consequently, the enthusiasm for screening, diagnosis, and treatment has been further reduced by the inadequate effectiveness of previous treatment methods. In recent years, progress has been made in the research and development of anti-HDV drugs, and a variety of drugs have already entered the clinical trial stage, and some have already been approved for commercialization in specific parts of the world. In this context, the world is also actively exploring effective ways to increase the HDV screening rate. The reflex test model can effectively raise the HDV screening rate and serve as a reference for HDV screening in other countries and regions, as demonstrated by studies conducted in the United Kingdom, France, and Spain, among others. This article will review the detection methods, screening, diagnosis, and treatment current status, as well as the progress in drug research and development, in order to help clinical physicians understand chronic HDV diagnosis and treatment.
